Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.

Nephrotoxicity is the major dose-limiting toxicity of cisplatin (CDDP). The aim of this study was to develop a pharmacokinetic (PK)/toxicodynamic (TD) model of CDDP-induced acute renal injury in rats and to simulate nephrotoxicity at various dosing rates. CDDP was administered to rats by a 30-s bolus or a 2-h infusion (1.0, 2.5, 5.0, and 7.5 mg/kg). Unbound CDDP concentrations in plasma and urine were determined up to 2 h after administration in the PK study, and plasma creatinine (Cr) levels were monitored for up to 7 days as an index of nephrotoxicity in the TD study. The PK was linear and was fitted with a traditional 2-compartment model. The TD was nonlinear and differed between dosing rates. The creatinine concentration profiles were fitted with a signal transduction-indirect response model. Population analysis using a nonlinear mixed-effect model was adapted to the developed PK/TD model and was well-validated. Dosing simulations from the developed population PK/TD model indicated that CDDP-induced nephrotoxicity was due to not only Cmax but also the time above the toxic concentration of CDDP. Prolongation of infusion time will not necessarily attenuate acute nephrotoxicity. This study demonstrated the potential utility of PK/TD modeling for preventing nephrotoxicity.

[1]  Y. Yamano,et al.  Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin. , 2014, Journal of pharmaceutical sciences.

[2]  Y. Kawai,et al.  Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. , 2005, Biological & pharmaceutical bulletin.

[3]  T. Schlott,et al.  Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation , 2004, British Journal of Cancer.

[4]  A. Hishida,et al.  Role of the increase in p21 in cisplatin-induced acute renal failure in rats. , 2001, Journal of the American Society of Nephrology : JASN.

[5]  K. Hanada,et al.  Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives , 2010, Pharmaceutical Research.

[6]  R. Magin,et al.  Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats , 1988, Cancer Chemotherapy and Pharmacology.

[7]  R. Henning,et al.  Epidermal Growth Factor Receptor Inhibitor PKI-166 Governs Cardiovascular Protection without Beneficial Effects on the Kidney in Hypertensive 5/6 Nephrectomized Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  W Wolf,et al.  Preparation and metabolism of a cisplatin/serum protein complex. , 1980, Chemico-biological interactions.

[9]  K. Hanada,et al.  Effects of Disopyramide and Verapamil on Renal Disposition and Nephrotoxicity of Cisplatin in Rats , 1999, Pharmaceutical Research.

[10]  J. Chládek,et al.  A rat model of early sepsis: relationships between gentamicin pharmacokinetics and systemic and renal effects of bacterial lipopolysaccharide combined with interleukin-2. , 2012, Biological & pharmaceutical bulletin.

[11]  H. Ogata,et al.  Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo , 1997, Cancer Chemotherapy and Pharmacology.

[12]  R. Franke,et al.  Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.

[13]  T. Nakao,et al.  Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. , 2006, Journal of pharmacological sciences.

[14]  R. Jelliffe,et al.  Aminoglycoside Nephrotoxicity: Modeling, Simulation, and Control , 2003, Antimicrobial Agents and Chemotherapy.

[15]  K. Hanada,et al.  Pharmacokinetics and Toxicodynamics of Cisplatin and Its Metabolites in Rats: Relationship between Renal Handling and Nephrotoxicity of Cisplatin , 2000, The Journal of pharmacy and pharmacology.

[16]  A. Ohtsu,et al.  Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer , 2012, Cancer Chemotherapy and Pharmacology.

[17]  A. Vickers,et al.  Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology , 2004, Toxicologic pathology.

[18]  O. Suzuki,et al.  Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  K. Hanada,et al.  Effect of Buthionine Sulphoximine, Glutathione and Methimazole on the Renal Disposition of Cisplatin and on Cisplatin‐induced Nephrotoxicity in Rats: Pharmacokinetic‐Toxicodynamic Analysis , 2000, The Journal of pharmacy and pharmacology.

[20]  G. Ramesh,et al.  Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. , 2004, Kidney international.

[21]  D. Stepensky,et al.  Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic–pharmacodynamic modeling analysis , 2014, Journal of clinical pharmacology.

[22]  H. Ogata,et al.  Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients , 1996, Cancer Chemotherapy and Pharmacology.

[23]  W. Evans,et al.  Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. , 1981, Cancer treatment reports.

[24]  J. Balthasar,et al.  Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  M. Leibbrandt,et al.  Differential toxicity of cisplatin, carboplatin, and CI-973 correlates with cellular platinum levels in rat renal cortical slices. , 1995, Toxicology and applied pharmacology.

[26]  Augusto Silva,et al.  Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation , 2007, Apoptosis.

[27]  O. Suzuki,et al.  Trace analysis of platinum in blood and urine by ESI-MS-MS , 2007, Forensic Toxicology.

[28]  M. Fakih,et al.  Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors , 2005, Clinical Cancer Research.

[29]  F. Lokiec,et al.  Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. , 2004, British journal of clinical pharmacology.

[30]  J. Verweij,et al.  Population pharmacokinetics of cisplatin in adult cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[31]  A. Hishida,et al.  Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  C. Plato,et al.  Evaluation of bioimpedance spectroscopy for the measurement of body fluid compartment volumes in rats. , 2012, Journal of pharmacological and toxicological methods.

[33]  T. Boulikas,et al.  Low renal toxicity of lipoplatin compared to cisplatin in animals. , 2004, Anticancer research.

[34]  J. Verweij,et al.  Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Verweij,et al.  Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.